Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.

Heba Shawky,Reem El-Shenawy,Naiera M Helmy

Human antibodies（2021）

引用 0|浏览0

暂无评分

摘要

Baseline MIP-1β/IL-12p40 ratio represents a non-invasive prognostic biomarker that would provide shorter treatment duration and minimizes the emergence of drug-resistant variants in HCV genotype 4-patients.

查看译文

关键词

Chronic HCV,DAA therapy,SVR12,chemokine profile,prognostic biomarker,treatment failure

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要